85
Participants
Start Date
February 10, 2020
Primary Completion Date
December 31, 2035
Study Completion Date
December 31, 2035
Onasemnogene Abeparvovec-xioi
Onasemnogene abeparvovec-xioi is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the cytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec-xioi administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Sydney Children's Hospital, Randwick
Universitair Ziekenhuis Gent, Ghent
Columbia University Medical Center, New York
National Taiwan University Hospital, Taipei
Instituto Gianninia Gaslini, Genova
Clinic for Special Children, Strasburg
Children's Hospital of Philadelphia, Philadelphia
Universita Degli Studi Di Milano, Milan
Istituto Neurologico di Ricerca, Milan
John Hopkins Hospital - David M. Rubenstein Child Health Building, Baltimore
Virginia Commonwealth University, Richmond
Children's Hospital of The King's Daughters, Norfolk
Duke University, Durham
Nationwide Children's Hospital, Columbus
Spectrum Health Hospitals Helen DeVos Children's Hospital, Grand Rapids
University of Wisconsin, Madison, Madison
Ann Robert H. Lurie Children's Hospital of Chicago, Chicago
Washington Unviersity School of Medicine in Saint Louis, St Louis
Hôpital Armand Trousseau, Paris
Children's Health Specialty Center Dallas Campus, Dallas
Children's Hospital Colorado, Aurora
University of Utah Health, Salt Lake City
Stanford University Medical Center, Palo Alto
Massachusetts General Hospital, Boston
Boston Children's Hospital, Boston
Centre de Référence des Maladies Neuromusculaires, Liège
Children's Hospital of Eastern Ontario Research Institute, Ottawa
Fondazione Policlinico Universitario Agostino Gemelli, Roma
Tokyo Women's Medical University Hospital, Tokyo
Great Ormond Street Hospital for Children NHS Foundation Trust, London
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Lead Sponsor
Novartis Gene Therapies
INDUSTRY